Johnsons bid for alion in us biotech bid of $1.75B us recently to access hep c treatments , gilead $20B MC with hep c approval, etanta in $440M cash deal for their hep c treatment research... ahz valued well below these prices for 3 known products..crazy.
terry
ireckon that secret kgb lab is working on hep c, hiv aids as proactive mentioned months ago, the market has ignored it, analogous viral dna to hsv and hpv, phase 2 hsv we know about is starting by dec, thousands of oz volunteers for that unlike phase 1 or phase 3. Maybe other uncurable viruses like ebola or the cold or sanofi related virus treatments..
Please tell us terry what you know they are working on in that lab. Must be something like this, they are 12 months ahead of us at all times. Pr fraser becoming CEO and chairman of admedus vaccines is great news, employed more staff I hear and more director than lab technician getting more senior as he should..pump out more research and treatments if the young graduates do the lab work for you than yourself. With extra funding from ahz he is freed up to do more impt cutting edge work instead oftime consuming lab work.
we know hsv phase2 due to start soon as is hpv ph1. Must be big to be so secret..maybe proactive knew long time ago or predicted it..why would proactive mention hiv or hepc if it wasnt it?
Ann: Admedus to showcase CardioCel at EACTS Annual Meeting, page-56
-
- There are more pages in this discussion • 26 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$18.00 |
Change
0.000(0.00%) |
Mkt cap ! $346.0M | |||
| Open | High | Low | Value | Volume |
| $18.00 | $18.10 | $17.70 | $58.64K | 3.27K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 109 | $18.00 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $18.10 | 700 | 1 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| AVR (ASX) Chart |